Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

NCT00801489 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

270

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11
Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1
de Novo Myelodysplastic Syndrome
High Risk Myelodysplastic Syndrome
Inv(16)
Myelodysplastic Syndrome With Excess Blasts
t(16;16)
t(8;21)
Untreated Adult Acute Myeloid Leukemia

Interventions

DRUG: Cytarabine
DRUG: Decitabine
BIOLOGICAL: Filgrastim-sndz
DRUG: Fludarabine Phosphate
DRUG: Gemtuzumab Ozogamicin
DRUG: Idarubicin
OTHER: Laboratory Biomarker Analysis

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]